{
  "id": 19051366,
  "title": "Alphatec Holdings director Demski buys $408,600 of common stock",
  "url": "https://urgent.news/2026/11/09/alphatec-holdings-director-demski-buys-408-600-of-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T00:01:28.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/alphatec-holdings-director-demski-buys-408600-of-common-stock-93CH-5010363"
  },
  "original_language": "en",
  "account": "David M. Demski, a director at Alphatec Holdings Inc. (NASDAQ:ATEC), recently increased his stake in the company by purchasing 60,000 shares of Alphatec Holdings common stock. This acquisition amounted to a total of $408,600, executed on October 30, 2026, at a price of $6.81 per share—the lowest point of the stock's 52-week trading range. The move appears to be part of a pre-planned strategy, as Demski had established a Rule 10b5-1 trading plan on June 15, 2026.\n\nAs of the purchase, Demski now directly owns 491,635 shares of Alphatec Holdings common stock. The stock has faced a steep decline of 64% year-to-date, but InvestorsPro analysts suggest that the company's net income is anticipated to increase this year. For those interested in a comprehensive analysis of ATEC's valuation and growth potential, the Pro Research Report is available for this and over 1,400 other US equities.\n\nIn related news, Alphatec Holdings reported third-quarter earnings for 2026 that fell short of Wall Street expectations. The company reported adjusted earnings of $0.09 per share, falling below the estimated $0.10, and revenue of $221.17 million, which was lower than the expected $225.44 million. Despite a 13% year-over-year revenue increase, the company encountered challenges with biologics sales, leading to a reduction in its full-year financial outlook. In reaction to these events, TD Cowen lowered its price target for Alphatec to $10 from $13, while Needham adjusted its target to $12 from $14, maintaining a Buy rating but citing the revenue miss and revised guidance as the reasons for the downgrade. These developments have prompted a reassessment of analysts' expectations for Alphatec, focusing on its financial performance and market conditions.",
  "summary": null,
  "key_points": [
    "Director Demski bought 60,000 shares of ATEC stock for $408,600 on Oct 30, 2026.",
    "Purchase made at $6.81 per share, lowest point of 52-week trading range.",
    "Demski now owns 491,635 shares, despite ATEC's 64% year-to-date decline."
  ],
  "editors_take": "A director's significant purchase at a yearly low signals internal confidence despite recent earnings misses and downward revisions to the company's full-year financial outlook.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}